Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
56
ESPR Quote, Financials, Valuation and Earnings
Last price:
$3.48
Seasonality move
:
13.7%
Day range:
$3.45 - $3.56
52-week range:
$0.69 - $4.18
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.26x
P/B ratio:
--
Volume:
2.5M
Avg. volume:
4.9M
1-year change:
88.11%
Market cap:
$831.9M
Revenue:
$332.3M
EPS (TTM):
-$0.54
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ESPR
Esperion Therapeutics, Inc.
|
$165.1M | $0.29 | 65.71% | -98.39% | $6.51 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.5M | $0.14 | 13.44% | 28.72% | $31.21 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
ANAB
AnaptysBio, Inc.
|
$87.1M | $0.93 | -26.24% | -13.87% | $67.92 |
|
NKTR
Nektar Therapeutics
|
$10.4M | -$3.50 | -3.45% | -973.8% | $129.86 |
|
RIGL
Rigel Pharmaceuticals, Inc.
|
$68.7M | $1.20 | 14.34% | 26.98% | $51.60 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ESPR
Esperion Therapeutics, Inc.
|
$3.48 | $6.51 | $831.9M | -- | $0.00 | 0% | 2.26x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$23.99 | $31.21 | $4.1B | 15.44x | $0.00 | 0% | 3.86x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$336.19 | $457.00 | $44.6B | 148.95x | $0.00 | 0% | 12.08x |
|
ANAB
AnaptysBio, Inc.
|
$54.19 | $67.92 | $1.5B | -- | $0.00 | 0% | 9.51x |
|
NKTR
Nektar Therapeutics
|
$73.73 | $129.86 | $1.3B | -- | $0.00 | 0% | 76.03x |
|
RIGL
Rigel Pharmaceuticals, Inc.
|
$35.46 | $51.60 | $643.6M | 5.75x | $0.00 | 0% | 2.31x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ESPR
Esperion Therapeutics, Inc.
|
408.15% | 2.534 | 109.82% | 0.65x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.064 | 5.64% | 2.51x |
|
ANAB
AnaptysBio, Inc.
|
109.28% | 0.036 | 41.03% | 8.52x |
|
NKTR
Nektar Therapeutics
|
66.26% | 7.810 | 16.97% | 4.07x |
|
RIGL
Rigel Pharmaceuticals, Inc.
|
34.11% | 0.668 | 11.84% | 1.94x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ESPR
Esperion Therapeutics, Inc.
|
$46M | -$10M | -60.77% | -- | -11.41% | -$23.9M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
ANAB
AnaptysBio, Inc.
|
$75.7M | $34.7M | -22.38% | -367.62% | 45.47% | -$27.4M |
|
NKTR
Nektar Therapeutics
|
$11.6M | -$31.5M | -54.14% | -327.67% | -267.45% | -$48.9M |
|
RIGL
Rigel Pharmaceuticals, Inc.
|
$64.7M | $28.4M | 111.09% | 273.99% | 40.92% | $24M |
Esperion Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns ESPR or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -35.89% compared to Esperion Therapeutics, Inc.'s net margin of 25.76%. Esperion Therapeutics, Inc.'s return on equity of -- beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital ESPREsperion Therapeutics, Inc.52.71% -$0.16 $146.5M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About ESPR or ACAD?
Esperion Therapeutics, Inc. has a consensus price target of $6.51, signalling upside risk potential of 87.03%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.21 which suggests that it could grow by 30.1%. Given that Esperion Therapeutics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Esperion Therapeutics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ESPREsperion Therapeutics, Inc.3 1 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is ESPR or ACAD More Risky?
Esperion Therapeutics, Inc. has a beta of 1.088, which suggesting that the stock is 8.755% more volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock ESPR or ACAD?
Esperion Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ESPR or ACAD?
Esperion Therapeutics, Inc. quarterly revenues are $87.3M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Esperion Therapeutics, Inc.'s net income of -$31.3M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Esperion Therapeutics, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 15.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics, Inc. is 2.26x versus 3.86x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ESPREsperion Therapeutics, Inc.2.26x -- $87.3M -$31.3M ACADACADIA Pharmaceuticals, Inc.3.86x 15.44x $278.6M $71.8M
-
Which has Higher Returns ESPR or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -35.89% compared to Esperion Therapeutics, Inc.'s net margin of 16.99%. Esperion Therapeutics, Inc.'s return on equity of -- beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital ESPREsperion Therapeutics, Inc.52.71% -$0.16 $146.5M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About ESPR or ALNY?
Esperion Therapeutics, Inc. has a consensus price target of $6.51, signalling upside risk potential of 87.03%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 35.94%. Given that Esperion Therapeutics, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Esperion Therapeutics, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ESPREsperion Therapeutics, Inc.3 1 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is ESPR or ALNY More Risky?
Esperion Therapeutics, Inc. has a beta of 1.088, which suggesting that the stock is 8.755% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock ESPR or ALNY?
Esperion Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ESPR or ALNY?
Esperion Therapeutics, Inc. quarterly revenues are $87.3M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Esperion Therapeutics, Inc.'s net income of -$31.3M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Esperion Therapeutics, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 148.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics, Inc. is 2.26x versus 12.08x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ESPREsperion Therapeutics, Inc.2.26x -- $87.3M -$31.3M ALNYAlnylam Pharmaceuticals, Inc.12.08x 148.95x $1.1B $186.4M
-
Which has Higher Returns ESPR or ANAB?
AnaptysBio, Inc. has a net margin of -35.89% compared to Esperion Therapeutics, Inc.'s net margin of 19.8%. Esperion Therapeutics, Inc.'s return on equity of -- beat AnaptysBio, Inc.'s return on equity of -367.62%.
Company Gross Margin Earnings Per Share Invested Capital ESPREsperion Therapeutics, Inc.52.71% -$0.16 $146.5M ANABAnaptysBio, Inc.99.2% $0.52 $317M -
What do Analysts Say About ESPR or ANAB?
Esperion Therapeutics, Inc. has a consensus price target of $6.51, signalling upside risk potential of 87.03%. On the other hand AnaptysBio, Inc. has an analysts' consensus of $67.92 which suggests that it could grow by 25.33%. Given that Esperion Therapeutics, Inc. has higher upside potential than AnaptysBio, Inc., analysts believe Esperion Therapeutics, Inc. is more attractive than AnaptysBio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ESPREsperion Therapeutics, Inc.3 1 0 ANABAnaptysBio, Inc.9 1 0 -
Is ESPR or ANAB More Risky?
Esperion Therapeutics, Inc. has a beta of 1.088, which suggesting that the stock is 8.755% more volatile than S&P 500. In comparison AnaptysBio, Inc. has a beta of 0.354, suggesting its less volatile than the S&P 500 by 64.645%.
-
Which is a Better Dividend Stock ESPR or ANAB?
Esperion Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AnaptysBio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics, Inc. pays -- of its earnings as a dividend. AnaptysBio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ESPR or ANAB?
Esperion Therapeutics, Inc. quarterly revenues are $87.3M, which are larger than AnaptysBio, Inc. quarterly revenues of $76.3M. Esperion Therapeutics, Inc.'s net income of -$31.3M is lower than AnaptysBio, Inc.'s net income of $15.1M. Notably, Esperion Therapeutics, Inc.'s price-to-earnings ratio is -- while AnaptysBio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics, Inc. is 2.26x versus 9.51x for AnaptysBio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ESPREsperion Therapeutics, Inc.2.26x -- $87.3M -$31.3M ANABAnaptysBio, Inc.9.51x -- $76.3M $15.1M
-
Which has Higher Returns ESPR or NKTR?
Nektar Therapeutics has a net margin of -35.89% compared to Esperion Therapeutics, Inc.'s net margin of -301.29%. Esperion Therapeutics, Inc.'s return on equity of -- beat Nektar Therapeutics's return on equity of -327.67%.
Company Gross Margin Earnings Per Share Invested Capital ESPREsperion Therapeutics, Inc.52.71% -$0.16 $146.5M NKTRNektar Therapeutics98.34% -$1.87 $252.2M -
What do Analysts Say About ESPR or NKTR?
Esperion Therapeutics, Inc. has a consensus price target of $6.51, signalling upside risk potential of 87.03%. On the other hand Nektar Therapeutics has an analysts' consensus of $129.86 which suggests that it could grow by 67.41%. Given that Esperion Therapeutics, Inc. has higher upside potential than Nektar Therapeutics, analysts believe Esperion Therapeutics, Inc. is more attractive than Nektar Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings ESPREsperion Therapeutics, Inc.3 1 0 NKTRNektar Therapeutics7 0 0 -
Is ESPR or NKTR More Risky?
Esperion Therapeutics, Inc. has a beta of 1.088, which suggesting that the stock is 8.755% more volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.341, suggesting its more volatile than the S&P 500 by 34.126%.
-
Which is a Better Dividend Stock ESPR or NKTR?
Esperion Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ESPR or NKTR?
Esperion Therapeutics, Inc. quarterly revenues are $87.3M, which are larger than Nektar Therapeutics quarterly revenues of $11.8M. Esperion Therapeutics, Inc.'s net income of -$31.3M is higher than Nektar Therapeutics's net income of -$35.5M. Notably, Esperion Therapeutics, Inc.'s price-to-earnings ratio is -- while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics, Inc. is 2.26x versus 76.03x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ESPREsperion Therapeutics, Inc.2.26x -- $87.3M -$31.3M NKTRNektar Therapeutics76.03x -- $11.8M -$35.5M
-
Which has Higher Returns ESPR or RIGL?
Rigel Pharmaceuticals, Inc. has a net margin of -35.89% compared to Esperion Therapeutics, Inc.'s net margin of 40.17%. Esperion Therapeutics, Inc.'s return on equity of -- beat Rigel Pharmaceuticals, Inc.'s return on equity of 273.99%.
Company Gross Margin Earnings Per Share Invested Capital ESPREsperion Therapeutics, Inc.52.71% -$0.16 $146.5M RIGLRigel Pharmaceuticals, Inc.93.16% $1.46 $178.5M -
What do Analysts Say About ESPR or RIGL?
Esperion Therapeutics, Inc. has a consensus price target of $6.51, signalling upside risk potential of 87.03%. On the other hand Rigel Pharmaceuticals, Inc. has an analysts' consensus of $51.60 which suggests that it could grow by 45.52%. Given that Esperion Therapeutics, Inc. has higher upside potential than Rigel Pharmaceuticals, Inc., analysts believe Esperion Therapeutics, Inc. is more attractive than Rigel Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ESPREsperion Therapeutics, Inc.3 1 0 RIGLRigel Pharmaceuticals, Inc.3 2 0 -
Is ESPR or RIGL More Risky?
Esperion Therapeutics, Inc. has a beta of 1.088, which suggesting that the stock is 8.755% more volatile than S&P 500. In comparison Rigel Pharmaceuticals, Inc. has a beta of 1.111, suggesting its more volatile than the S&P 500 by 11.137%.
-
Which is a Better Dividend Stock ESPR or RIGL?
Esperion Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics, Inc. pays -- of its earnings as a dividend. Rigel Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ESPR or RIGL?
Esperion Therapeutics, Inc. quarterly revenues are $87.3M, which are larger than Rigel Pharmaceuticals, Inc. quarterly revenues of $69.5M. Esperion Therapeutics, Inc.'s net income of -$31.3M is lower than Rigel Pharmaceuticals, Inc.'s net income of $27.9M. Notably, Esperion Therapeutics, Inc.'s price-to-earnings ratio is -- while Rigel Pharmaceuticals, Inc.'s PE ratio is 5.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics, Inc. is 2.26x versus 2.31x for Rigel Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ESPREsperion Therapeutics, Inc.2.26x -- $87.3M -$31.3M RIGLRigel Pharmaceuticals, Inc.2.31x 5.75x $69.5M $27.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 21
RingCentral, Inc. [RNG] is up 34.37% over the past day.
Sell
9
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
72
SNSE alert for Feb 21
Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.
